Capacidad antioxidante de la melatonina: Su papel defensivo contra afecciones relacionadas con la edad

Medicina Clinica

Volumn 110, Issue 17, 1998, Pages 668-676

  López, Beatriz Díaz ^a,c   Colmenero Urquijo, M Dolores ^a   Fernández, Bernardo Marin ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Centro Universitario   (Spain)

^c Faculty de Medicina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BETA CAROTENE; ESTROGEN; FREE RADICAL; MANNITOL; MELATONIN; PROLACTIN; TOCOPHEROL;

CELL LEVEL; DEGENERATIVE DISEASE; HUMAN; PATHOPHYSIOLOGY; REVIEW; SENESCENCE;

AGE FACTORS; AGED; AGING; ANIMALS; ANTIOXIDANTS; FEMALE; FREE RADICALS; HUMANS; LIFE EXPECTANCY; MALE; MELATONIN; MICE; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; RATS;

EID: 0004486383     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Cardinali DC. Models in neuroendocrinology. Neurohumoral pathways to the pineal gland. Trends Neurosci 1979; 2: 250-253.
2. Reiter RJ. Pineal melatonin: cell biology of its physiological interactions. Endocrine Rev 1991; 12: 151-180.
3. Reiter RJ. Melatonin: the chemical expression of darkness. Mol Cell Endocrinol 1991; 79: 153-158.
4. Reiter RJ. Action spectra, dose-response relationships and temporal aspects of light's effects on the pineal gland. Ann NY Acad Sci 1985; 453; 215-230.
5. Reiter RJ. Pineal gland: interface between the photoperiodic environment and the endocrine system. Trends Endocrinol Metab 1991; 2: 9-13.
6. Reiter RJ. The melatonin rhythm. Both a clock and a calendar Experientia 1993; 49: 554-664.
7. Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 1993; 17: 347-357.
8. Reiter RJ, Poeggeler B, Tan DX, Chen LD, Manchester LC, Guerrero JM. Antioxidant capacity of melatonin: a novel action not requiring a receptor. Neuroendocrinol Lett 1993a; 15: 103-116.
9. Poeggeler B, Balzer I, Hardeland R, Lerchl A, Pineal hormone melatonin oscillates also in the dinoflagellate Gonyaulax polyedra. Natuwissenschaften 1991; 78: 268-269.
10. Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD, Saarela S. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann NY Acad Sci 1994a; 719: 1-12.
11. Reiter RJ. The aging pineal gland and its physiological consequences. Bio Essays 1992; 14; 169-175.
12. Iguchi H, Kato K, Ibayashi. Age dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-29.
13. Sack RL, Lewy AJ, Erb DC, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res 1986; 3: 379-388.
14. Reiter RJ, Tan DX, Poeggeler B, Chen LD, Menendez-Pelaez A Melatonin, free radicals and cancer initiation. En: Maestroni GJM, Conti A, Reiter RJ, editores. Advances in Pineal Research (Vol. 4). Londres: John Libbely and Co. Ltd. 1994b; 211-228.
15. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin oxidative damage and aging: a hypothesis. J Pineal Res 1993; 14: 151-168.
16. Pang SF, Allen AE. Extra-pineal melatonin in the retina: its regulation and physiological function. En: Reiter RJ, editor. Pineal Res Rev (Vol. 4). Nueva York: Alan R. Liss, 1986; 55-95.
17. Menendez-Pelaez A. Melatonin and other indoles in the rodent Harderian gland: regulation and physiological significance. En: Reiter RJ, Lukanszyk A, editores. Advances in Pineal Research (Vol. 4). Londres: John Libbey Limited, 1990; 75-80.
18. Mhatre MC, Van Jaarveld AS, Reiter RJ. Melatonin in the lacrimal gland: first demostration and experimental manipulation. Biochem Biophys Res Commun 1988; 153: 1.186-1.192.
19. Huether G, Poeggeler B, Reimer A, George A. Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulating of melatonin synthesis and release in the gastrointestinal tract. Life Sci 1992; 51: 945-953.
20. Henden T, Stokkan KA, Riter RJ, Nonaka KO, Lerchl A, Jones DJ, The age-associated reduction in pineal β-adrenergic receptor density is prevented by life-long food restriction in rats. Biol Signals 1992; 1: 34-39.
21. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions Endocrine Res 1991; 12: 151-180.
22. Stankov B, Franschini F, Reiter RJ. Melatonin binding sites in the central nervous system. Brain Res Rev 1991; 16: 245-256.
23. 3H-acetylmelatonin. Nature New Biology 1972; 237: 117-118.
24. Reppert SM, Chez RA, Anderson A, Klein DC. Maternal-fetal transfer of melatonin in the non-human primate. Pediatr Res 1979; 13: 788-790.
25. Fridovich J. The biology of oxygen radicals. Science 1978; 201: 875-879.
26. a ed.). Madrid: Ed. Aguilar, 1962; 286-287.
27. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 1988; 333: 664-666.
28. Altmant KI, Gerber GB, Okada SA, En: Radiation chemistry. Nueva York: Academic Press, 1970; vols. 2 y 3.
29. Mead JF. Free radicals mechanisms of lipid damage and consequences for cellular membranes. En: Pryor WA, editor. Free radicals in biology, Nueva York: Academic Press, 1976; 1: 51-68.
30. Scott G. Atmospheric oxidation and antiooxidants. Nueva York: Elsevier, 1965.
31. Loach PA, Hales BJ. Free radicals in photosynthesis. En: Pryor WA, editor. Free radicals in biology. Nueva York: Academic Press, 1976; 1: 199-237.
32. Nohl H, Hegner D. Do mitochondria produce oxygen radicals in vivo? Eur J Biochem 1978; 82: 863-866.
33. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979; 59: 527-605.
34. Klebanoff SJ. Oxigen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980; 93: 480-489.
35. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59: 1.609-1.623.
36. Cooper KH. La revolución de los antioxidantes. En: Salud y naturismo. Barcelona: Ed. Martínez Roca, S.A., 1995; 38-39.
37. Harman D. Free radical theory of aging. Mutation Res 1992; 275: 257-266.
38. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford: Clarendon Press, 1991.
39. Davis KSA. Protein damage and degradation by the oxygen radicals, I. General aspects. J Biol Chem 1987; 262: 9.895-9.901.
40. Cerruti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cell 1991; 3: 1-12.
41. Reed DJ. Regulation of reductive processes by glutathione. Biochem Pharmacol 1986; 35: 7-13.
42. Marklund SL, Kling PA, Nilsson S, Ohman M. Plasma extracellular-superoxide dismutase in the acute phase response induced by surgical trauma and inflammatory disorders. Scand J Clin Lab Invest 1987; 47: 567-570.
43. Perez-Campo R, Lopez-Torres M, Paton D, Sequeros L, Barja de Quiroga G. Lung antioxidant enzymes, peroxidation, glutation system and oxygen sumption in catalase inactivted young and old R. perezi frogs. Mech Age Dev 1990; 56: 281-292.
44. Sohal RS, Svensson I, Sohal BH, Brunk WT. Superoxide anion radical production in different animal species. Mech Age Dev 1989; 49: 129-135.
45. a ed.). Oxford: Clarenton Press, 1989; 418-419.
46. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995; 9: 526-533.
47. Flohe L, Gunziea WA, Landenstein R. Glutathione peroxidases. En: Arias IM, Jacoby, editores. Glutathione: metabolism and function, Nueva York: Raven Press, 1976; 115-138.
48. De Duve C, Hayaishi O. Tocopherol, oxygen and biomembranes. En: De Duve C, Hayaishi O, editores. Nueva York: Elsevier (North Holland), 1978.
49. Kohen R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA 1988; 85: 3.175-3.179.
50. Cutler RC. Peroxide-producing potential of tissues: inverse correlation with longevity of mammalian species. Proc Natl Acad Sci USA 1985; 82: 4.798-4.802.
51. Reveilland I, Niedzwiechi A, Bensch KG, Fleming JE. Expression of bovine Superoxide dismutasa Drosophila melanogaster arguments resistance to oxidant stress. Mol Cell Biol 1991; 11: 632-640.
52. Epstein CJ, Avraham KB, Lovett M, Smith S, Elroy-Stein O, Rotman G et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down's syndrome. Proc Natl Acad Sci USA 1987; 84: 8.044-8.048.
53. Ceballos-Picot I, Nicole A, Brian P, Grimber G, Delacourte A, Defossex A et al. Neuronal-specific expression of human copper-zinc Superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome. Brain Res 1991; 552: 198-214.
54. Sinet PM. Metabolism of oxigen derivates in Down's syndrome En: Sinex FM. Merril CR, editores. Alzheimer's disease, Down's syndrome, and aging. Ann NY Acad Sci 1982; 396: 83-94.
55. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
56. Tan DX, Poeggeler B, Reiter RJ, Chen LD, Chen S, Manchester LC et al. The pineal hormone melatonin inhibits DNA adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett 1993; 70: 65-71.
57. Abe M, Reiter RJ, Orhii PB. Hara M, Poeggeler B. Inhibitory effect of melatonin on cataract formation in newborn rats: evidence for an antioxidative role for melatonin. J Pineal Res 1994; 17: 94-100.
58. Melchiory D, Reiter RJ, Attia AM, Burgos A, Nistico G. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci 1994; 56: 83-89.
59. Swerynek E, Mitsushi A, Reiter RJ, Barlow-Walden L, Chen LD, McCabe TJ et al. Melatonin administration prevents lipopolysaccharide-induced oxidative damage in phenobarbital-treated animals. J Cell Biochem 1995; 58: 436-444.
60. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-722.
61. 2+-de-pendent ATPase in cardiac sarcolema. J Pineal Res 1993; 14: 178-183.
62. Reiter RJ. Mini-Review. The melatonin message: duration versus coincidence hypotheses. Life Sci 1987; 40: 2.119-2.131.
63. Diaz B, Marin B. Response to melatonin in brain areas implicated in the sexual cycle of the rat. Brain Res 1984; 296: 333-338.
64. Miyazaky T. Sueoka AM, Dharmarajan SJ, Atlas GB, Bulkley, Wallach EE. Effect of inhibition of oxigen free radical on ovulation and progesterone production by the in-vitro perfused rabbit ovary, J Reprod Fert 1991; 91: 207-212.
65. Tamarkin L, Reppert SM, Orloff DJ, Klein DC, Yellon SM, Goldman BD. Ontogeny of the pineal melatonin rhythm in the Syrian (Mesocricetus auratus) and Siberian (Phodopus sungorus) hamsters and in the rat. Endocrinology 1980; 99: 1.534-1.541.
66. Abe M, Reiter RJ, Orhii PB, Hara M, Poeggeler B. Inhibitory effect of melatonin on cataract formation in newborn rats. J Pineal Res 1994; 17: 94-100.
67. Harman D. Free radical theory of aging: the free radical deseases. Age 1984; 7: 111-131.
68. 1 mice. J Gerontol 1968; 23: 476-482.
69. Emanuel NM. Free radicals and the action of inhibitors of radical processe under pathological states and aging in living organisms and man. Q Rev Biophys 1976; 9: 283-308.
70. Silberberg RS, Jarrett SR, Silberberg M. Longevity of female mice kept on various dietary regimens during growth. J Gerontol 1962; 17: 239-244.
71. Matsuo M. Age-related alterations in antioxidative defense. En: Yu BP, editor. Free radicals in aging. Boca Raton, Florida: CRC Press, 1993; 143-181.
72. Floyd RA, Carney JM. The role of metal ions in oxidative processes and aging. Toxicol Indust Health 1993; 9: 197-214.
73. Reiter RJ. The pineal gland and melatonin in relation to aging: a summary of the theories and the data. Exp Gerontol 1994; 30: 199-212.
74. Rice-Evans C, Burdon R. Free radical-lipid interactions and their pathological consequences. Prog Lipid Res 1993; 32: 71-110.
75. Niki E, Noguchi N, Gotoh N. Dynamics of lipid peroxidation and its inhibition by antioxidants. Biochem Soc Trans 1993; 21: 313-317.
76. Borg DC. Oxygen radicals and tissue damage. En: Tarr M, Samson F, editores. Oxygen free radicals and tissue damage. Boston: Birkhäuser, 1993; 12-53.
77. Diaz Lopez B, Menendez-Patterson A, Marin Fernandez B. Role of the pineal gland in the activity of nervous structures involved in sexual processes of the male rat. Comp Biochem Physiol 1987; 88A: 55-59.
78. Alexiuk NAM, Vriend JP. Extrahypothalamic effects of melatonin administration on serotonin and norepinephrine synthesis in female syriam hamsters. J Neural Transm 1993; 94: 45-53.
79. Pieri C, Marra M, Moroni F, Decchiono R, Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 1994; 55: 271-276.
80. Barlow-Walden L, Reiter RJ, Abe M, Pablos MI, Menendez-Pelaez A, Chen LD et al. Melatonin stimulates brain gluthatione peroxidase activity. Neurochem Int 1995; 26: 497-502.
81. Sinet PM, Heikkila RE, Cohen G. Hydrogen peroxide production in rat brain in vivo. J Neurochem 1980; 34: 1.421-1.428.
82. Tan DX, Reiter RJ, Chen LD, Poeggelier B, Manchester LD, Barlow-Walden LR. Both phisiological and pharmacological levels of melatonin reduce DNA adduct formation indiced by the carcinogen safrole in vivo. Carcinogenesis 1994; 15: 215-218.
83. Chen LD, Leal BZ, Reiter RJ, Abe M, Sewerynek E, Melchiori D et al. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular gluthatione concentrations. Cancer Lett 1995; 91: 153-159.
84. Blask DE. The pineal gland: an oncostatic gland. En: Reiter RJ, editor. The pineal gland. Nueva York: Raven Press, 1984; 253-284.
85. Hill SM, Blask DE. Effect of the pineal gland hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6.121-6.126.
86. Hill SM, Springgs LL, Simon MA, Muraoka H, Blask DE. The growth inhibitory action of melatonin on strogen-sensitive human breast cancer cells is linked to the estrogen response system. Cancer Lett 1992; 64: 249-256.
87. Fuyura Y, Yamamoto K, Kohno N, Ku Y, Saitoh Y. 5-fluorouracil attenuates an oncostatic effect of melatonin on strogen-sensitive human breast cancer cells (MCF-7). Cancer Lett 1994; 81: 95-98.
88. Blask DE, Hill SM. Effects of melatonin in cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm 1986; 21: 433-449.
89. Karasek M, Kunest-Radek J, Stepien H, Pawlikcwski M. Melatonin inhibits the proliferation of estrogen-induced rat pituitary tumor cells in vitro. Neuroendocrinol Lett 1988; 10: 135-144.
90. Cos S, Blask D. Effects of melatonin on growth factor activity in MCF-7 human breast cancer cells. En: Arendt J, Pevet P, editores. Advances in pineal research. Londres: John Libbey and Co. Ltd, 1991; 5: 365-367.
91. Blask D, Wilson ST. Melatonin and oncostatic signal transduction: evidence for a novel mechanism involving glutathione and nitric oxide. En: Moller M, Pevet P, editores. Advances in pineal research. Londres: John Libbey and Co. Ltd, 1994; 8: 465-471.
92. Waldhauser F, Steger H. Changes in melatonin secretion with age and pubescence. J Neural Transm 1986; 21: 183-197.